Back
UTHR logo

United Therapeutics Corporation (UTHR)

Biotechnology
UTHR · NASDAQ NMS - GLOBAL MARKET · USD
New to investing? How to read this page →
$549.32
+3.17%

Weekly undervalued picks (like UTHR)

Price · 1 year
Loading live analysis…
Loading analysis…

Intrinsic Investor is for research and education only. Not financial advice.

Key metrics

EPS
$27.86
ROE
20.3%
Gross margin
86.6%
Debt/Equity
Revenue growth
-1.6%
P/B ratio
Beta
Forward P/E

United Therapeutics Corporation — company intelligence

Earnings surprises

Q2 2026$7.27 vs $6.97 est+4.3%
Q1 2026$5.82 vs $7.01 est-16.9%
Q4 2025$7.70 vs $7.33 est+5.1%
Q3 2025$7.16 vs $7.33 est-2.3%

Analyst consensus · 22 analysts

18 Buy4 Hold0 Sell
Updated Oct 5, 2026

Insider activity · 90 days

0 buys179 sellsnet -177,777 shares
ROTHBLATT MARTINE ASell 600 · Sep 24, 2026
ROTHBLATT MARTINE ASell 437 · Sep 24, 2026
ROTHBLATT MARTINE ASell 2,160 · Sep 24, 2026

AI Valuation Narrative

Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.

Weekly undervalued picks (like UTHR)

Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.

Free. No spam. We only email once per week.

Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.